Organization
Ohio State University Medical Center
7 abstracts
Abstract
Efficacy and safety of encorafenib (enco) plus binimetinib (bini) in patients with BRAF V600E-mutant (BRAFV600E) metastatic non-small cell lung cancer (NSCLC) from the phase 2 PHAROS study.Org: Samsung Medical Center, Vall d’Hebron University Hospital/VHIO, Memorial Sloan Kettering Cancer Center, Tennessee Oncology, PLLC, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Factors associated with severe immune checkpoint inhibitor-induced pneumonitis.Org: The Ohio State University - James Cancer Hospital, The Ohio State University - Biostatistics Department, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University College of Medicine, The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH,
Abstract
Hospitalization for immune related toxicity and overall survival (OS) among patients with metastatic non-small cell lung cancer (NSCLC) treated with first-line pembrolizumab.Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Ohio State University Comprehensive Canvcer Hospital, Center for Biostatistics and Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University Wexner Medical Center and Comprehensive Cancer Center,
Abstract
Sex differences in prognostic utility of peripheral eosinophil count in first-line immune checkpoint therapy against metastatic NSCLC.Org: Ohio State University Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, The Ohio State University College of Medicine, James Cancer Hospital and Solove Research Institute and The Ohio State University Wexner Medical Center, The Ohio State University Wexner Medical Center,
Abstract
Real world outcomes of patients treated with first line chemo-immunotherapy (IO) for small cell lung cancer (SCLC): Impact of brain metastases and patterns of subsequent therapy.Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, Ohio State University Comprehensive Canvcer Hospital, Adena Health System, The Ohio State College of Medicine, Center for Biostatistics and Department of Biomedical Informatics,
Abstract
Patterns of weight change and overall survival (OS) during first-line pembrolizumab treatment in patients with non-small cell lung cancer (NSCLC).Org: The Ohio State University Comprehensive Cancer Center and Pelotonia Institute for Immuno-Oncology, Columbus, OH, James Cancer Hospital & Solove Research Institute, Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University College of Medicine, Ohio State University Wexner Medical Center,
Abstract
Incidence of central nervous system metastases (mCNS) and overall survival (OS) in patients with stage III non-small cell lung cancer (NSCLC) treated with definitive chemoradiation followed by durvalumab (Durva).Org: Ohio State University Wexner Medical Center, Adena Health System, Center for Biostatistics and Department of Biomedical Informatics, The Ohio State University Comprehensive Cancer Center – James Cancer Hospital & Solove Research Institute, Ohio State University James Cancer Hospital Department of Radiation Oncology,